FidoCure^® Veterinary Team Blog

After FidoCure^® enabled treatment, Sam exceeded the 5-7  month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.

With combination therapy that included targeted therapy guided by  FidoCure® genomic sequencing, Heidi has survived over a year following her initial diagnosis of mesothelioma and is still going strong.

With a combination approach that included FidoCure® therapy, Scout has lived for 1.5 years after his initial diagnosis of telangiectatic osteosarcoma.

As you are likely aware, global supply chain issues are causing shortages of crucial raw drug ingredients needed to produce targeted therapy medications. These shortages are having a significant impact on the veterinary compounding pharmacy industry, and we know that you, your patients and pet parents are feeling the effects.

We want you to know that the FidoCure® team shares your sense of urgency and we are working hard to ensure that no dog is left without the cancer treatments it needs.

Providing access to life-saving therapies is one of our core values, and we are committed to putting you and your patients first.

As we celebrate World Veterinary Day, we would like to express our heartfelt appreciation to the entire veterinary community. We at FidoCure are proud to help serve your work and your patients with our precision medicine platform. You are the front line fighter of cancer in pets  and we are honored to partner in this battle against cancer to improve the quality of life for countless dogs.

With the help of FidoCure® therapy, Ruby had a great quality of life for 2 years after her initial diagnosis of transitional cell carcinoma.

With the help of FidoCure® therapy, Phinn has lived a great quality of life for over 18 months after his initial diagnosis of amelanotic melanoma and is still going strong!

With surgery and FidoCure® therapy, Callie is alive and well almost 20 months after her initial diagnosis of jejunal adenocarcinoma.